MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2022 International Congress

    Women with Parkinson’s Disease (PD) and High Coffee Use Have a Shorter Time to Medication Initiation

    K. Wong, E. Brown, C. Meng, C. Tanner (San Francisco, USA)

    Objective: Investigate how coffee use prior to PD diagnosis affects medication initiation in PD. Background: Population studies show a decreased incidence of PD for men…
  • 2022 International Congress

    PD+: A comprehensive, user-friendly mobile application for clinicians treating Parkinson’s Disease

    E. Shah, T. Khachatryan, N. Phielipp, S. Isfahani (Orange, USA)

    Objective: We developed a mobile application that converts dopaminergic medication dosages and calculates total Levodopa (L-dopa) equivalent daily dose (LEDD) in a Parkinson’s Disease (PD)…
  • 2022 International Congress

    Delayed Osmotic Demyelination Syndrome- An Evolving Spectrum

    S. Garg, K. Shetty (Bengaluru, India)

    Objective: To report a case of osmotic demyelination syndrome (ODS) with continuing clinical and radiological worsening beyond its previously established temporal course. Background: ODS is…
  • MDS Virtual Congress 2021

    Tinospora Cordifolia protects against Rotenone induced degeneration of dopaminergic neurons in mouse model of Parkinson’s disease

    S. Singh, H. Birla (Varanasi, India)

    Objective: To explore the neuroprotective mechanisms of T. cordifolia ethanolic extract against Rotenone (ROT)-intoxicated mouse model through proteomics approach. Background: The death of dopaminergic (DAergic)…
  • MDS Virtual Congress 2021

    Efficacy and safety of Levodopa-Carbidopa Intestinal Gel in the treatment of Parkinson’s Disease

    E. Londero, A P. Dos Santos, R. Braga, R. de Barros, L. Dos Reis, G. Freire (Salvador, Brazil)

    Objective: Our study aims to analyze the efficacy and safety of Levodopa-carbidopa intestinal gel (LCIG) in Parkinson's disease (PD). Background: Oral Levodopa is considered to…
  • MDS Virtual Congress 2021

    Effects of levodopa dose on temporal dynamics of cortical activity and postural control in people with Parkinson’s disease

    FAB. Barbieri, FAS. Araújo-Silva, FBS. Santinelli, LFI. Imaizumi, APS. Silveira, LHV. Palucci Vieira, LA. Alcock (Bauru, Brazil)

    Objective: The purpose of this study was to evaluate the temporal dynamics of cortical activity and postural control for the first levodopa dose of the…
  • MDS Virtual Congress 2021

    Pharmacokinetic–pharmacodynamics of levodopa/carbidopa following subcutaneous infusion with ND0612: Results from the BeyoND pharmacokinetic substudy

    T. Birnberg, L. Adar, W. Poewe, M. Bjornsson, M. Karlsson (Rehovot, Israel)

    Objective: To evaluate the pharmacokinetic–pharmacodynamic relationships between levodopa plasma exposure and motor treatment response in patients with Parkinson’s disease (PD) treated with ND0612 and adjunct…
  • MDS Virtual Congress 2021

    Effect of H. pylori Infection on L-DOPA Pharmacokinetics in Patients with Parkinson’s disease.

    S. Oda, Y. Saitoh, J. Takei, S. Watanabe, Y. Mukai, Y. Takahashi (Kodaira, Japan)

    Objective: To evaluate whether Helicobactor pylori (H.pylori) infection affects the pharmacokinetics of L-DOPA in patients with Parkinson’s disease (PD). Background: H. pylori infects gastric mucosa…
  • MDS Virtual Congress 2021

    Quantitative 3D movement analysis detects motor improvement earlier than MDS-UPDRS in a levodopa challenge test

    R. Barbosa, M. Medonça, R. Oliveira, M. Santos, A. Abreu, P. Bastos, P. Pita-Lobo, A. Valadas, L. Correia-Guedes, J. Ferreirajos, M. Rosa, R. Matias, M. Coelho (Lisbon, Portugal)

    Objective: Characterize the response of gait in a levodopa challenge test (LCT) in PD using inertial sensor-based 3D movement analysis and MDS-UPDRS. Background: Quantitative 3D…
  • MDS Virtual Congress 2021

    CVT-301 (levodopa inhalation powder): meta-analysis of safety in patients with Parkinson’s disease (PD)

    P. Lewitt, P. Zhao, A. Corbin, D. Kegler-Ebo, B. Blank (West Bloomfield, USA)

    Objective: Safety results from a phase 3, double-blind study of CVT-301 in patients with PD were combined with results from a 4-week, phase 2b, double-blind,…
  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • …
  • 62
  • Next Page »
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley